UCB (OTCMKTS:UCBJY) Shares Pass Below 50-Day Moving Average - Here's What Happened

Key Points

• UCB crossed below its 50‑day moving average, trading as low as $142.53 and last at $144.61 versus a 50‑day MA of $152.75 and a 200‑day MA of $142.63.
• Analyst sentiment improved: Wolfe Research upgraded UCB to "strong‑buy" on Feb. 23, and MarketBeat shows a consensus rating of "Buy" (two Strong Buy, one Hold).
• Solid fundamentals and product portfolio: UCB has a quick ratio of 1.01, current ratio of 1.35 and debt‑to‑equity of 0.29, and sells key drugs including CIMZIA, VIMPAT and NEUPRO.

UCB SA (OTCMKTS:UCBJY - Get Free Report)'s stock price crossed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $152.75 and traded as low as $142.53. UCB shares last traded at $144.61, with a volume of 57,166 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, Wolfe Research upgraded shares of UCB to a "strong-buy" rating in a research note on Monday, February 23rd. Two research analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Buy".

UCB Stock Up 0.5%

The company has a quick ratio of 1.01, a current ratio of 1.35 and a debt-to-equity ratio of 0.29. The company has a 50 day simple moving average of $152.75 and a two-hundred day simple moving average of $142.63.

About UCB

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson's disease, rheumatoid arthritis and Crohn's disease.

The company's commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson's disease and restless legs syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.